Dr. Scott M. Ravis, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,546
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
MO license 2006009464 · IN license 01059923A · KS license 31651 -
Dermatopathology (Pathology) Physician
KS license 31651
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Kansas City Skin and Cancer Center LLC (16 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,546
- Services billed
- 8,614
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 6,600 | 20 |
| Destruction of precancer skin growth, 2-14 growths | 2,367 | 287 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,251 | 881 |
| Biopsy of related skin growth, first growth | 449 | 361 |
| Destruction of precancer skin growth, 1 growth | 436 | 361 |
| Destruction of precancer skin growth, 15 or more growths | 369 | 253 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 367 | 301 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 298 | 165 |
| Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | 160 | 130 |
| Biopsy of related skin growth, each additional growth | 139 | 108 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 98 payments worth $2,104 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $461 |
|---|---|
| AbbVie Inc. | $325 |
| Janssen Biotech, Inc. | $233 |
| UCB, Inc. | $202 |
| Sun Pharmaceutical Industries Inc. | $180 |
| Regeneron Healthcare Solutions, Inc. | $90.83 |
| Amgen Inc. | $90.80 |
| E.r. Squibb & Sons, L.l.c. | $86.94 |
| Food and Beverage | $1,996 |
|---|---|
| Education | $109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Sep 17, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| AbbVie Inc. Jan 7, 2025 | Education SKYRIZI · IMMUNOLOGY · in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.